Previous Nav
Net Change on 15-09-2025
PersonalFN Rating
Category
Assets (Cr.)
Expense Ratio
Fund House
Launch Date
Benchmark
Minimum Investment (₹)
Minimum Addl Investment (₹)
Exit Load (%)
Minimum SIP Investment (₹)
Minimum STP Investment (₹)
Minimum SWP Investment (₹)
52 Week Low Nav (₹)
52 Week Low Nav Date
52 Week High Nav (₹)
52 Week High Nav Date
Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised
Sun Pharmaceutical Industries Ltd.
Divi's Laboratories Ltd.
Max Healthcare Institute Ltd.
Cipla Ltd.
TREPS
Lonza Group
Lupin Ltd.
Torrent Pharmaceuticals Ltd.
Mankind Pharma Ltd.
Fortis Healthcare Ltd.
Gland Pharma Ltd.
Krishna Institute of Medical Sciences Ltd.
Acutaas Chemicals Ltd.
Concord Biotech Ltd.
Aster DM Healthcare Ltd.
Laurus Labs Ltd.
Polymedicure Ltd.
Jupiter Life Line Hospitals Ltd.
Abbott India Ltd.
Biocon Ltd.
Alkem Laboratories Ltd.
Aether Industries Ltd.
Anthem Biosciences Ltd.
Rainbow Children's Medicare Ltd.
Aurobindo Pharma Ltd.
Cohance Lifesciences Ltd.
Vijaya Diagnostic Centre Ltd.
Pfizer Ltd.
Sanofi Consumer Healthcare India Ltd.
Gufic Biosciences Ltd.
Akums Drugs & Pharmaceuticals Ltd.
Medplus Health Services Ltd.
182 DAY T-BILL 20.11.25
Net Receivable / Payable
Pharmaceuticals & Drugs
Hospital & Healthcare Services
Miscellaneous
Medical Equipment/Supplies/Accessories
Chemicals
Retailing
Cash
Equity
Sovereign
SBI Healthcare Opportunities Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to SBI Mutual Fund. It was launched on 01-Jan-2013 and currently has an AUM of ₹3,963.38 crore. SBI Healthcare Opportunities Fund is benchmarked against BSE Health Care - TRI as primary index and BSE SENSEX - TRI as secondary index.
The NAV of SBI Healthcare Opportunities Fund ended down ₹-1.51(-0.3%)yesterday to ₹498.3237.
Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Ltd., and
The SBI Healthcare Opportunities Fund is managed by Tanmaya Desai .
9th Floor, Crescenzo, C - 38 & 39 G Block, BKC, Bandra (East) Mumbai - 400 051